Status:
COMPLETED
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Advanced Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metas...
Eligibility Criteria
Inclusion
- Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease
- Greater than 18 years of age
- A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy
- Able to provide written informed consent
- Proficient in the English language and self-reports as literate
- Must have an active email address or access to a smart device on which text messages can be received
Exclusion
- Women cannot be breast-feeding
- Does not have regular access to the internet
- Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist
- Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change
Key Trial Info
Start Date :
July 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03229083
Start Date
July 24 2019
End Date
February 14 2025
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester - Wilmot Cancer Institute
Rochester, New York, United States, 14642